<DOC>
	<DOC>NCT01689220</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).</brief_summary>
	<brief_title>A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<criteria>Korean patients aged â‰¥ 20 years of age at the day of obtaining the informed consent Patients with histologically confirmed diagnosis of the following: PTCL, not otherwise specified (PTCLNOS) Anaplastic Large Cell Lymphoma (ALCL ALKpositive/negative) Angioimmunoblastic Tcell Lymphoma (AITL) Have relapsed or refractory to at least one prior systemic chemotherapy for the above disease (currently requiring therapy) Have at least 1 evaluable lesion Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Life expectancy of at least 3 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>